Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Sees No “Strategic Reason” To Keep OTC Unit, McKinnell Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm still weighing options for consumer unit, sees bid covering capital gains tax as “attractive” alternative to spinning off division, according to CEO.

You may also be interested in...

J&J Buys Pfizer Consumer Division For $16.6 Bil.

Johnson & Johnson CEO William Weldon says the deal will make the firm's portfolio "more balanced," with 40% devoted to pharmaceuticals, 35% to medical devices and 25% to consumer products.

Blame China? Experts Advise Congress, Industry Take A Wider View

The global scope of food safety is becoming apparent, and recent problems with products imported from China are but a part of U.S. food safety concerns, industry experts say





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts